CD8A and neoplasm: The effectiveness of immunotherapy, particularly programmed death 1 (PD-1)/programmed cell death-Ligand 1 (PD-L1) immune checkpoint inhibitors, which has become a key treatment option, depends on the tumor immune microenvironment, such as the infiltration of CD8+ T cells into the tumor[4,5].